{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:45:51Z","timestamp":1779889551962,"version":"3.53.1"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:00:00Z","timestamp":1669334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"CSPC Ouyi Pharmaceutical Co., Ltd"},{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai","doi-asserted-by":"publisher","award":["21ZR1414700"],"award-info":[{"award-number":["21ZR1414700"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The anti-tumor activity of nab-paclitaxel followed by epirubicin\/cyclophosphamide (EC) as neoadjuvant chemotherapy (NAC) in Asian patients remain unclear, particularly in the aggressive subtype triple-negative breast cancer (TNBC). This study aimed to evaluate the efficacy and safety of this NAC regimen in TNBC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this Simon\u2019s two-stage, phase II study, treatment-na\u00efve patients with unilateral primary invasive TNBC were enrolled. Eligible patients received nab-paclitaxel 125 mg\/m2 weekly on day 1 for 12 weeks, followed by dose-dense EC (epirubicin 90 mg\/m2; cyclophosphamide 600 mg\/m2) on day 1 for four 2-week cycles. The primary endpoint was the total pathological complete response (tpCR, ypT0\/is ypN0) rate.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 55 eligible patients were enrolled and treated. After NAC, tpCR and breast pathological complete response were respectively observed in 43.1% (95% CI, 29.3-57.8) and 49.0% (95% CI, 34.8-63.4) of 51 evaluable patients for pathological response evaluation. 44 had an objective response as their best response (80.0%; 95% CI, 67.0-89.6). No correlations between clinicopathological variables and pathological\/clinical response were observed. Grade 3 or more adverse events (AEs) occurred in 63.6% of 55 patients. The most frequent AEs were alopecia. No treatment-related surgical delay or death occurred.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Nab-paclitaxel followed by dose-dense EC as NAC demonstrates promising anti-tumor activity and acceptable tolerability for patients with TNBC. (ClinicalTrials.gov Identifier: NCT03799679).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyac223","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T12:32:24Z","timestamp":1669379544000},"page":"86-e76","source":"Crossref","is-referenced-by-count":8,"title":["<i>Nab<\/i>-paclitaxel Followed by Dose-dense Epirubicin\/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study"],"prefix":"10.1093","volume":"28","author":[{"given":"Yin","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Breast Surgery, Fudan University Shanghai Cancer Center and Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Shanghai Medical College, Fudan University , Shanghai , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Fudan University Shanghai Cancer Center and Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Shanghai Medical College, Fudan University , Shanghai , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Hua","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Fudan University Shanghai Cancer Center and Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Shanghai Medical College, Fudan University , Shanghai , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4503-148X","authenticated-orcid":false,"given":"Zhi-Ming","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Fudan University Shanghai Cancer Center and Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Shanghai Medical College, Fudan University , Shanghai , People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,25]]},"reference":[{"issue":"4","key":"2023042213185695800_CIT0001","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s12282-016-0748-6","article-title":"Preoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial","volume":"24","author":"Futamura","year":"2017","journal-title":"Breast Cancer"},{"issue":"12","key":"2023042213185695800_CIT0002","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2217\/nnm-2018-0485","article-title":"Efficacy of two-weekly nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy for breast cancer","volume":"14","author":"Xie","year":"2019","journal-title":"Nanomedicine (London, England)"},{"issue":"23","key":"2023042213185695800_CIT0003","doi-asserted-by":"crossref","first-page":"6360","DOI":"10.1158\/1078-0432.CCR-13-0916","article-title":"Neoadjuvant therapy as a platform for drug development and approval in breast cancer","volume":"19","author":"Bardia","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2023042213185695800_CIT0004","first-page":"103","article-title":"Relevance of pathological complete response after neoadjuvant therapy for breast cancer","volume":"10","author":"Pennisi","year":"2016","journal-title":"Breast Cancer"},{"issue":"8","key":"2023042213185695800_CIT0005","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1093\/annonc\/mdt131","article-title":"Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with her2-overexpressing breast cancer","volume":"24","author":"Kim","year":"2013","journal-title":"Ann Oncol"},{"issue":"12","key":"2023042213185695800_CIT0006","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1007\/s40265-017-0774-5","article-title":"Neoadjuvant therapy for breast cancer: established concepts and emerging strategies","volume":"77","author":"Steenbruggen","year":"2017","journal-title":"Drugs"},{"issue":"4","key":"2023042213185695800_CIT0007","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1007\/s13277-013-0786-z","article-title":"Is breast cancer in young Asian women more aggressive than in Caucasians? A cross-sectional analysis","volume":"34","author":"Tea","year":"2013","journal-title":"Tumour Biol"},{"issue":"2","key":"2023042213185695800_CIT0008","doi-asserted-by":"crossref","first-page":"e0210891","DOI":"10.1371\/journal.pone.0210891","article-title":"Tailored neoadjuvant epirubicin, cyclophosphamide and nanoparticle albumin-bound paclitaxel for breast cancer: the phase II neonab trial-clinical outcomes and molecular determinants of response","volume":"14","author":"Murphy","year":"2019","journal-title":"PLoS One"},{"issue":"3","key":"2023042213185695800_CIT0009","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S1470-2045(15)00542-2","article-title":"Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (geparsepto\u2014gbg 69): a randomised, phase 3 trial","volume":"17","author":"Untch","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"2023042213185695800_CIT0010","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/ijc.33830","article-title":"Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (neocart): Results from a multicenter, randomized controlled, open-label phase ii trial","volume":"150","author":"Zhang","year":"2022","journal-title":"Int J Cancer"},{"issue":"12","key":"2023042213185695800_CIT0011","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1093\/annonc\/mdt361","article-title":"Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (gbg 44)","volume":"24","author":"Gerber","year":"2013","journal-title":"Ann Oncol"},{"issue":"7","key":"2023042213185695800_CIT0012","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1586\/14737140.7.7.919","article-title":"Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy","volume":"7","author":"Henderson","year":"2007","journal-title":"Expert Rev Anticancer Ther"},{"issue":"15_suppl","key":"2023042213185695800_CIT0013","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/jco.2014.32.15_suppl.1051","article-title":"Nabrax: neoadjuvant therapy of breast cancer with weekly single-agent nab-paclitaxel\u2014final efficacy and biomarkers analysis of geicam 2011-02 trial","volume":"32","author":"Martin","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"2023042213185695800_CIT0014","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.clbc.2018.06.012","article-title":"Randomized multicenter phase ii trial of neoadjuvant therapy comparing weekly nab-paclitaxel followed by fec with docetaxel followed by fec in her2(-) early-stage breast cancer","volume":"18","author":"Kuwayama","year":"2018","journal-title":"Clin Breast Cancer"},{"issue":"22","key":"2023042213185695800_CIT0015","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1200\/JCO.2008.18.5397","article-title":"Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer","volume":"27","author":"Gradishar","year":"2009","journal-title":"J Clin Oncol"},{"key":"2023042213185695800_CIT0016","first-page":"371","article-title":"Update on taxane development: new analogs and new formulations","volume":"6","author":"Yared","year":"2012","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"2023042213185695800_CIT0017","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1001\/jamaoncol.2017.4612","article-title":"Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with erbb2\/her2-negative breast cancer-the evaluating treatment with neoadjuvant abraxane (etna) trial: A randomized phase 3 clinical trial","volume":"4","author":"Gianni","year":"2018","journal-title":"JAMA Oncol"},{"issue":"Suppl 6","key":"2023042213185695800_CIT0018","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/annonc\/mdt178","article-title":"Small-cell lung cancer (sclc): esmo clinical practice guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Fruh","year":"2013","journal-title":"Ann Oncol"},{"issue":"18","key":"2023042213185695800_CIT0019","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.2217\/fon-2021-1647","article-title":"Keynote-522, impassion031 and geparnuevo: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer","volume":"18","author":"Rizzo","year":"2022","journal-title":"Future Oncol"},{"issue":"10257","key":"2023042213185695800_CIT0020","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (impassion031): a randomised, double-blind, phase 3 trial","volume":"396","author":"Mittendorf","year":"2020","journal-title":"Lancet (London, England)"},{"issue":"8","key":"2023042213185695800_CIT0021","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/annonc\/mdz158","article-title":"A randomised phase ii study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of geparnuevo study","volume":"30","author":"Loibl","year":"2019","journal-title":"Ann Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/1\/86\/50064999\/oyac223.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/1\/86\/50064999\/oyac223.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,22]],"date-time":"2023-04-22T13:19:27Z","timestamp":1682169567000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/1\/86\/6847064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,25]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,11,25]]},"published-print":{"date-parts":[[2023,1,18]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyac223","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2022,11,25]]}}}